Older women unlikely to benefit from HPV vax

A new study concludes that women over the age of 40 are unlikely to benefit from an HPV vaccine.

Researchers tracked the experiences of 9,000 Costa Rican women ages 19 to 97 years, screening them for HPV infections, which can trigger cervical cancer. The rate of newly detected infections plunge from 35 percent for women 19 to 25 to 13.5 percent for women over the age of 42. Typically those infections cleared up without treatment.

"Because the HPV vaccine can only prevent infections, and these women are not getting that many new infections, the potential benefit of HPV vaccination among older women is very limited," says Dr. Ana Cecilia Rodríguez, the lead author.

- check out the study abstract
- here's the report from the New York Times

Suggested Articles

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.